The US Food and Drug Administration has temporarily suspended requirements of the modified Clozapine Risk Evaluation and Mitigation Strategy so pharmacists can dispense the antipsychotic without a REMS dispense authorization and wholesalers may continue to ship it to pharmacies and health care settings without confirming enrollment in the program.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?